Alnylam Pharmaceuticals (ALNY) Projected to Post Quarterly Earnings on Thursday

Alnylam Pharmaceuticals (NASDAQ:ALNY) is expected to release its Q3 2025 results before the market opens on Thursday, October 30th. Analysts expect Alnylam Pharmaceuticals to post earnings of $1.39 per share and revenue of $943.3730 million for the quarter. Alnylam Pharmaceuticals has set its FY 2025 guidance at EPS.Individuals can find conference call details on the company’s upcoming Q3 2025 earningreport page for the latest details on the call scheduled for Thursday, October 30, 2025 at 8:30 AM ET.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its quarterly earnings data on Thursday, July 31st. The biopharmaceutical company reported $0.32 EPS for the quarter, beating analysts’ consensus estimates of ($0.54) by $0.86. The company had revenue of $773.69 million for the quarter, compared to analyst estimates of $633.54 million. Alnylam Pharmaceuticals had a negative net margin of 12.96% and a negative return on equity of 273.52%. Alnylam Pharmaceuticals’s quarterly revenue was up 17.3% on a year-over-year basis. During the same period in the previous year, the business posted ($0.13) earnings per share. On average, analysts expect Alnylam Pharmaceuticals to post $-2 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Alnylam Pharmaceuticals Stock Performance

Shares of ALNY stock opened at $464.90 on Thursday. The company has a current ratio of 2.80, a quick ratio of 2.75 and a debt-to-equity ratio of 4.10. Alnylam Pharmaceuticals has a 12-month low of $205.87 and a 12-month high of $495.55. The company has a market cap of $60.94 billion, a price-to-earnings ratio of -188.22 and a beta of 0.36. The stock has a 50 day simple moving average of $458.55 and a 200-day simple moving average of $356.79.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on the stock. BMO Capital Markets upped their price target on shares of Alnylam Pharmaceuticals from $450.00 to $470.00 and gave the stock an “outperform” rating in a research report on Friday, September 5th. Wall Street Zen lowered Alnylam Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Sunday, October 12th. JPMorgan Chase & Co. lowered their price objective on shares of Alnylam Pharmaceuticals from $475.00 to $473.00 and set an “overweight” rating for the company in a research report on Monday, October 13th. Wolfe Research upgraded Alnylam Pharmaceuticals from an “underperform” rating to a “peer perform” rating in a research note on Monday, August 4th. Finally, Evercore ISI increased their price target on Alnylam Pharmaceuticals from $280.00 to $515.05 and gave the stock an “outperform” rating in a research note on Thursday, September 11th. Twenty-three investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Alnylam Pharmaceuticals has an average rating of “Moderate Buy” and an average price target of $466.92.

Insider Transactions at Alnylam Pharmaceuticals

In other Alnylam Pharmaceuticals news, Director Colleen F. Reitan sold 18,000 shares of the company’s stock in a transaction on Tuesday, September 9th. The stock was sold at an average price of $467.60, for a total transaction of $8,416,800.00. Following the completion of the sale, the director directly owned 775 shares in the company, valued at $362,390. This represents a 95.87% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Michael W. Bonney sold 11,250 shares of the firm’s stock in a transaction that occurred on Monday, August 18th. The shares were sold at an average price of $450.00, for a total transaction of $5,062,500.00. Following the completion of the transaction, the director owned 16,804 shares of the company’s stock, valued at approximately $7,561,800. This trade represents a 40.10% decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders sold 98,144 shares of company stock worth $44,160,261. Corporate insiders own 1.50% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of ALNY. Geneos Wealth Management Inc. lifted its holdings in Alnylam Pharmaceuticals by 372.3% during the first quarter. Geneos Wealth Management Inc. now owns 222 shares of the biopharmaceutical company’s stock worth $60,000 after acquiring an additional 175 shares during the period. NewEdge Advisors LLC lifted its position in shares of Alnylam Pharmaceuticals by 70,300.0% during the 2nd quarter. NewEdge Advisors LLC now owns 704 shares of the biopharmaceutical company’s stock valued at $229,000 after buying an additional 703 shares during the last quarter. Flow Traders U.S. LLC purchased a new stake in Alnylam Pharmaceuticals in the 2nd quarter worth about $241,000. Brighton Jones LLC bought a new stake in Alnylam Pharmaceuticals in the 4th quarter valued at about $243,000. Finally, ICONIQ Capital LLC bought a new position in Alnylam Pharmaceuticals during the second quarter worth about $263,000. Hedge funds and other institutional investors own 92.97% of the company’s stock.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.